PPARGC1A and non-small cell lung carcinoma: Cisplatin resistance involves metabolic reprogramming through modulation of the ROS and PGC-1α signaling pathways in NSCLC cell lines, but, treatment with OXPHOS inhibitors such as metformin or rotenone improves cisplatin sensitivity [42].